Evaluating the effects of bariatric surgery on diabetic kidney disease
A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy
This study is testing whether bariatric surgery can help people with diabetic kidney disease improve their kidney health by losing weight.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06661174 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to assess the efficacy of bariatric surgery in patients with rapidly progressing diabetic nephropathy. It will establish a cohort of diabetic kidney disease patients undergoing intensive weight loss treatment to evaluate its impact on renal prognosis. The study will also focus on constructing a prediction model to forecast improvements in renal outcomes following weight loss. Both surgical and non-surgical therapies will be considered in the treatment approach.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 with a BMI over 25 and significant diabetic kidney disease.
Not a fit: Patients with certain conditions such as active tumors, autoimmune diseases, or those taking glucocorticoids may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved renal outcomes for patients with diabetic nephropathy through effective weight loss strategies.
How similar studies have performed: Previous studies have shown promising results in the impact of bariatric surgery on metabolic conditions, suggesting potential success for this approach in diabetic nephropathy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Age 18 to 65 years old;
* BMI\>25Kg/m2 or abdominal obesity (i.e. waist circumference\>90cm for men and\>85cm for women);
* eGFR\<30ml/min/1.73m2 or urinary microalbumin≥300mg/g, eGFR\<60ml/min/1.73m2.
Exclusion Criteria:
* Patients who are taking glucocorticoids;
* Combined with tumors; ③Combined with autoimmune diseases; ④Serum albumin\<25g/L.
Where this trial is running
Beijing, Beijing Municipality
- China-Japan Friendship Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Hua Meng — China-Japan Friendship Hospital
- Study coordinator: Nianrong Zhang
- Email: znrsd@163.com
- Phone: +86 188 1048 8650
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.